Coverage at a glance
| Indication | Coverage |
|---|---|
| Type 2 diabetes | Covered with prior authorization |
Plan type: Commercial non-Medicare. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
Coverage by indication
| Step therapy |
What the prior authorization needs:
- Documented diagnosis of type 2 diabetes
- Prior trial of another antidiabetic agent, per the BCBS Illinois GLP-1 agonist criteria
- Quantity limits apply per the July 2026 Multi-Tier Basic Annual Drug List (form 2656-1N IL): 30 tablets per 30 days for the 7 mg and 14 mg doses, and 30 tablets per 180 days for the 3 mg starting dose
Policy 23466.0726. Source: BCBSIL Prior Authorization/Step Therapy Program, GLP-1 (glucagon-like peptide-1) Agonists clinical criteria 23466.0726. payer prior-authorization policy. Verified August 28, 2026.
Recent change: As of the July 2026 formulary, Rybelsus is listed and covered for type 2 diabetes with prior authorization.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time. Some participants get a placebo, decided at random.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does BCBS Illinois cover Rybelsus?
Blue Cross and Blue Shield of Illinois covers Rybelsus for type 2 diabetes, with prior authorization required through its pharmacy benefit manager, Prime Therapeutics. Approval needs a documented type 2 diabetes diagnosis and a prior trial of another antidiabetic agent, and quantity limits apply. Rybelsus is not covered for weight loss, because it is FDA-approved for type 2 diabetes only. The weight-loss semaglutide is Wegovy, which BCBS Illinois lists separately with its own prior authorization. This reflects the published policy verified August 2026.
What does BCBS Illinois require to approve Rybelsus?
For type 2 diabetes: true
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
